INVITRO ACTIVITY OF BU-2313B AGAINST ANAEROBIC-BACTERIA
INVITRO ACTIVITY OF BU-2313B AGAINST ANAEROBIC-BACTERIA
复制标题
DOI：
10.1159/000238076
复制
发表时间：
1982-01-01
期刊：
影响因子：
3.3
通讯作者：
THADEPALLI, H
中科院分区：
文献类型：
--
作者：
BANSAL, MB;DHAWAN, VK;THADEPALLI, H
通过与克林霉素、氯霉素和头孢西丁对 265 种临床（人类）厌氧菌进行比较，评估了新型抗生素 BU-2313B 的抗菌功效。 BU-2313B 在 2 μg/ml 浓度下抑制 66 种脆弱拟杆菌分离株中的 88%；克林霉素、氯霉素和头孢西丁在2、8和16μg/ml浓度下分别抑制98%、97%和92%。 BU-2313B 的疗效比氯霉素和头孢西丁高数倍，但比克林霉素低 8 倍。
The antimicrobial efficacy of BU-2313B, a new antibiotic, was evaluated in comparison with clindamycin, chloramphenicol and cefoxitin against 265 clinical (human) anaerobic isolates. BU-2313B inhibited 88% of 66 isolates of Bacteroides fragilis tested at 2 .mu.g/ml; clindamycin, chloramphenicol and cefoxitin inhibited 98, 97 and 92% of them at 2, 8 and 16 .mu.g/ml, respectively. BU-2313B was several-fold more effective than chloramphenicol and cefoxitin, but it was 8 times less effective than clindamycin.